Pear Bio
Boston
About Pear Bio
Pear Bio is a Boston and London-based AI-enabled biotech company. We develop functional precision medicine-guided therapeutics for patients with hard-to-treat cancers. We take tumor biopsies and blood from cancer patients to find new targets with multi-omics. We then test the efficacy of generated drug candidates directly on patient tumor samples using a proprietary immune-microtumor system. We have best-in-class and first-in-class internal drug discovery programs, and we are using our 3D immune-microtumor platform to position our drug candidates in the right indications/populations and in smarter combination therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $19.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2023)
- Website: pearbio.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/pear-bio-36996 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.